Ideaya Biosciences Inc
NASDAQ:IDYA 4:00:00 PM EDT
| Market Cap (Intraday) | 1.84B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $21.64 |
| 50-Day MA | $20.00 |
| 200-Day MA | $23.90 |
Ideaya Biosciences Inc Stock, NASDAQ:IDYA
5000 Shoreline Court, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.443.6209
Number of Employees: 131
Description
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.